Glycopyrronium Bromide

Glycopyrronium bromide is indicated for several conditions where reduction of cholinergic activity is beneficial.

• Maintenance therapy for chronic obstructive pulmonary disease (COPD) to improve lung function and reduce exacerbations.
• Adjunctive treatment in asthma when standard inhaled therapies are insufficient.
• Management of primary hyperhidrosis affecting the palms, soles, or axillae.
• Pre‑operative reduction of secretions in patients undergoing surgery.
• Off‑label use in certain gastrointestinal motility disorders under specialist supervision.

Side effects of glycopyrronium bromide reflect its anticholinergic activity and may vary in frequency.

Common

• Dry mouth, which may be bothersome but is usually mild.
• Constipation, often manageable with diet or laxatives.
• Blurred vision, typically transient.
• Urinary retention, especially in patients with prostate enlargement.

Serious

• Tachycardia or other cardiac rhythm disturbances.
• Severe allergic reactions such as anaphylaxis, rash, or facial swelling.
• Acute angle‑closure glaucoma, presenting with eye pain and visual changes.

Before prescribing glycopyrronium bromide, clinicians should evaluate several precautionary factors to ensure safe use.

• Assess for urinary tract obstruction or prostate enlargement, as anticholinergic effects may worsen retention.
• Use cautiously in patients with glaucoma, particularly narrow‑angle type.
• Monitor heart rate and rhythm in individuals with known cardiac disease.
• Consider dose adjustment or avoidance in pregnancy (Category C) and lactation.
• Review concomitant anticholinergic medications to avoid additive effects.
• Evaluate renal or hepatic impairment, as clearance may be altered.

Glycopyrronium bromide can interact with other drugs that influence cholinergic pathways or cardiac function.

Avoid

• Other anticholinergic agents (e.g., atropine, ipratropium) due to additive anticholinergic burden.
• Potent CYP3A4 inhibitors if the formulation is metabolized via this pathway (e.g., ketoconazole, clarithromycin).
• Medications that prolong the QT interval, increasing risk of arrhythmia.

Use with caution

• Beta‑agonists used for asthma or COPD, as combined bronchodilation may affect heart rate.
• Drugs that affect urinary retention (e.g., antihistamines, tricyclic antidepressants).
• Cardiac glycosides (e.g., digoxin) due to potential changes in heart rate.